This inventor holds 6 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, The United States of America. Active years: 2002-2009.
Location History:
- Germantown, MD (US) (2007)
- Takoma Park, MD (US) (2002 - 2009)
Company Filing History:
4 out of 3,690 
2 out of 255 
Years Active: 2002-2009
Title: Innovations in Vaccine Development by Anna P Durbin
Introduction
Anna P Durbin is a prominent inventor based in Takoma Park, MD (US). She has made significant contributions to the field of vaccine development, particularly in the area of parainfluenza virus (PIV) research. With a total of 6 patents to her name, her work has been instrumental in advancing our understanding of viral infections and their prevention.
Latest Patents
Among her latest patents, Durbin has developed attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines. These chimeric viruses are designed to be infectious and attenuated in humans and other mammals. They are useful individually or in combination in vaccine formulations for eliciting an immune response to PIV or other pathogens. Additionally, her patents include isolated polynucleotide molecules and vectors that incorporate a chimeric PIV genome or antigenome. This innovation combines a human or bovine PIV 'background' genome with heterologous genes or genome segments from different pathogens, enhancing the efficacy of vaccines.
Another notable patent involves the use of recombinant live-attenuated PIV as a vector to protect against diseases caused by PIV and respiratory syncytial virus (RSV). The chimeric PIVs developed by Durbin incorporate a PIV vector genome and one or more antigenic determinants of heterologous pathogens. These viruses are also infectious and attenuated, making them suitable for vaccine formulations aimed at eliciting immune responses against multiple pathogens.
Career Highlights
Durbin has worked with esteemed organizations, including the Department of Health and Human Services in the United States. Her research has significantly impacted public health, particularly in the development of vaccines that can combat viral infections effectively.
Collaborations
Throughout her career, Anna P Durbin has collaborated with notable colleagues such as Peter L Collins and Brian R Murphy. These partnerships have further enriched her research and contributed to the advancement of vaccine technology.
Conclusion
Anna P Durbin's innovative work in vaccine development, particularly her patents related to chimeric parainfluenza viruses, showcases her dedication to improving public health through scientific research. Her contributions continue to pave the way for new vaccine strategies that can protect against viral infections.